K00546
Based on 1 Customer Validation
K00546 is a potent CDK1 and CDK2 inhibitor with IC50s of 0.6 nM and 0.5 nM for CDK1/cyclin B and CDK2/cyclin A, respectively. K00546 is also a potent CDC2-like kinase 1 (CLK1) and CLK3 inhibitor with IC50s of 8.9 nM and 29.2 nM, respectively.
For research use only. We do not sell to patients.
- Purity: 99.48%
- CAS No.: 443798-47-8
- Formula: C15H13F2N7O2S2
- Molecular Weight:425.44
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
All VEGFR Isoforms
More
Biological Activity
|
Cdk1/cyclin B 0.6 nM (IC50) |
cdk2/cyclin A 0.5 nM (IC50) |
CLK1 8.9 nM (IC50) |
CLK3 29.2 nM (IC50) |
VEGF-R2 32 nM (IC50) |
GSK-3 140 nM (IC50) |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| A-375 | IC50 |
0.092 μM
Compound: 3n
|
In vitro inhibitory concentration against cell proliferation in human A375 (malignant melanoma),tumor cells
In vitro inhibitory concentration against cell proliferation in human A375 (malignant melanoma),tumor cells
|
[PMID: 15974571] |
| A-375 | IC50 |
92 nM
Compound: K00546
|
Antiproliferative activity against human A375 cells
Antiproliferative activity against human A375 cells
|
[PMID: 18077363] |
| HCT-116 | IC50 |
0.02 μM
Compound: 3n
|
In vitro inhibitory concentration against cell proliferation in human HCT116 (colon carcinoma) tumor cells
In vitro inhibitory concentration against cell proliferation in human HCT116 (colon carcinoma) tumor cells
|
[PMID: 15974571] |
| HCT-116 | IC50 |
20 nM
Compound: K00546
|
Antiproliferative activity against human HCT116 cells
Antiproliferative activity against human HCT116 cells
|
[PMID: 18077363] |
| HeLa | IC50 |
0.035 μM
Compound: 3n
|
In vitro inhibitory concentration against cell proliferation in human HeLa (cervical adenocarcinoma) tumor cells
In vitro inhibitory concentration against cell proliferation in human HeLa (cervical adenocarcinoma) tumor cells
|
[PMID: 15974571] |
| HeLa | IC50 |
35 nM
Compound: K00546
|
Antiproliferative activity against human HeLa cells
Antiproliferative activity against human HeLa cells
|
[PMID: 18077363] |
| HepG2 | IC50 |
>50 μM
Compound: 99302653
|
HARVARD: Cytotoxicity in HepG2 cell line
HARVARD: Cytotoxicity in HepG2 cell line
|
[PMID: 22586124] |
| HepG2 | IC50 |
0.472 μM
Compound: 99302653
|
HARVARD: Inhibition of liver stage Plasmodium berghei infection in HepG2 cells
HARVARD: Inhibition of liver stage Plasmodium berghei infection in HepG2 cells
|
[PMID: 22586124] |
| Sf9 | IC50 |
0.002 μM
Compound: Fig.8B, R1C2
|
Inhibition of His-tagged CDK1/cyclin B1 (unknown origin) expressed in Baculovirus infected Sf9 cells using histone H1 as substrate in presence of [gamma-33P]-ATP by radiometric filter binding assay
Inhibition of His-tagged CDK1/cyclin B1 (unknown origin) expressed in Baculovirus infected Sf9 cells using histone H1 as substrate in presence of [gamma-33P]-ATP by radiometric filter binding assay
|
[PMID: 30234987] |
| Sf9 | IC50 |
0.003 μM
Compound: Fig.8B, R1C2
|
Inhibition of His-tagged CDK2/cyclin E (unknown origin) expressed in Baculovirus infected Sf9 cells using histone H1 as substrate in presence of [gamma-33P]-ATP by radiometric filter binding assay
Inhibition of His-tagged CDK2/cyclin E (unknown origin) expressed in Baculovirus infected Sf9 cells using histone H1 as substrate in presence of [gamma-33P]-ATP by radiometric filter binding assay
|
[PMID: 30234987] |
| Sf9 | IC50 |
0.03 μM
Compound: Fig.8B, R1C2
|
Inhibition of GST-tagged CDK9/CyclinT1 (unknown origin) expressed in Baculovirus infected Sf9 cells using YSPTSPS-2 KK peptide as substrate as substrate in presence of [gamma-33P]-ATP by radiometric filter binding assay
Inhibition of GST-tagged CDK9/CyclinT1 (unknown origin) expressed in Baculovirus infected Sf9 cells using YSPTSPS-2 KK peptide as substrate as substrate in presence of [gamma-33P]-ATP by radiometric filter binding assay
|
[PMID: 30234987] |
| Sf9 | IC50 |
0.059 μM
Compound: Fig.8B, R1C2
|
Inhibition of GST-tagged CDK4/cyclin D1 (unknown origin) expressed in Baculovirus infected Sf9 cells using RPPTLSPIPHIPR peptide as substrate in presence of [gamma-33P]-ATP by radiometric filter binding assay
Inhibition of GST-tagged CDK4/cyclin D1 (unknown origin) expressed in Baculovirus infected Sf9 cells using RPPTLSPIPHIPR peptide as substrate in presence of [gamma-33P]-ATP by radiometric filter binding assay
|
[PMID: 30234987] |
| Sf9 | IC50 |
0.066 μM
Compound: Fig.8B, R1C2
|
Inhibition of GST-tagged CDK7/cyclinH/MAT1 (unknown origin) expressed in Baculovirus infected Sf9 cells using YSPTSPS-2 KK peptide as substrate as substrate in presence of [gamma-33P]-ATP by radiometric filter binding assay
Inhibition of GST-tagged CDK7/cyclinH/MAT1 (unknown origin) expressed in Baculovirus infected Sf9 cells using YSPTSPS-2 KK peptide as substrate as substrate in presence of [gamma-33P]-ATP by radiometric filter binding assay
|
[PMID: 30234987] |
| Sf9 | IC50 |
0.0002 μM
Compound: Fig.8B, R1C2
|
Inhibition of GST-tagged CDK5/p25 (unknown origin) expressed in Baculovirus infected Sf9 cells using histone H1 as substrate as substrate in presence of [gamma-33P]-ATP by radiometric filter binding assay
Inhibition of GST-tagged CDK5/p25 (unknown origin) expressed in Baculovirus infected Sf9 cells using histone H1 as substrate as substrate in presence of [gamma-33P]-ATP by radiometric filter binding assay
|
[PMID: 30234987] |
| Sf9 | IC50 |
0.2 nM
Compound: Fig.8B, R1C2
|
Inhibition of GST-tagged CDK5/p25 (unknown origin) expressed in Baculovirus infected Sf9 cells using histone H1 as substrate as substrate in presence of [gamma-33P]-ATP by radiometric filter binding assay
Inhibition of GST-tagged CDK5/p25 (unknown origin) expressed in Baculovirus infected Sf9 cells using histone H1 as substrate as substrate in presence of [gamma-33P]-ATP by radiometric filter binding assay
|
[PMID: 30234987] |
K00546 binds to the SLK ATP-binding site forming three hydrogen bonds with the kinase hinge residues E109 and C111. The sulphamoyl moiety of K00546 also interacts with the main chain of L40[1].
K00546 (compound 3n) also inhibits PKA, casein kinase-1, MAP kinase (ERK-2), calmodulin kinase, VEGF-R2, GSK-3 and PDGF-Rβ with IC50 values of 5.2 μM, 2.8 μM, 1.0 μM, 8.9 μM, 0.032 μM, 0.14 μM and 1.6 μM, respectively[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 443798-47-8
-
Appearance Solid
-
Molecular Weight 425.44
-
Formula C15H13F2N7O2S2
-
Color White to off-white
-
SMILES
S=C(N1N=C(NC2=CC=C(S(=O)(N)=O)C=C2)N=C1N)NC3=C(F)C=CC=C3F
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Solvent & Solubility
DMSO : 100 mg/mL (235.05 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Purity & Documentation
-
Data Sheet (277 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Portuguese - PT (251 KB)
-
Handling Instructions (2659 KB)
References
[1]. Ashley C W Pike, et al. Activation segment dimerization: a mechanism for kinase autophosphorylation of non-consensus sites. EMBO J. 2008 Feb 20;27(4):704-14. [Content Brief]
[2]. Ronghui Lin, et al. 1-Acyl-1H-[1,2,4]triazole-3,5-diamine analogues as novel and potent anticancer cyclin-dependent kinase inhibitors: synthesis and evaluation of biological activities. J Med Chem. 2005 Jun 30;48(13):4208-11. [Content Brief]
[3]. Oleg Fedorov, et al. Specific CLK inhibitors from a novel chemotype for regulation of alternative splicing. Chem Biol. 2011 Jan 28;18(1):67-76. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.3505 mL | 11.7525 mL | 23.5051 mL | 58.7627 mL |
| 5 mM | 0.4701 mL | 2.3505 mL | 4.7010 mL | 11.7525 mL | |
| 10 mM | 0.2351 mL | 1.1753 mL | 2.3505 mL | 5.8763 mL | |
| 15 mM | 0.1567 mL | 0.7835 mL | 1.5670 mL | 3.9175 mL | |
| 20 mM | 0.1175 mL | 0.5876 mL | 1.1753 mL | 2.9381 mL | |
| 25 mM | 0.0940 mL | 0.4701 mL | 0.9402 mL | 2.3505 mL | |
| 30 mM | 0.0784 mL | 0.3918 mL | 0.7835 mL | 1.9588 mL | |
| 40 mM | 0.0588 mL | 0.2938 mL | 0.5876 mL | 1.4691 mL | |
| 50 mM | 0.0470 mL | 0.2351 mL | 0.4701 mL | 1.1753 mL | |
| 60 mM | 0.0392 mL | 0.1959 mL | 0.3918 mL | 0.9794 mL | |
| 80 mM | 0.0294 mL | 0.1469 mL | 0.2938 mL | 0.7345 mL | |
| 100 mM | 0.0235 mL | 0.1175 mL | 0.2351 mL | 0.5876 mL |